Charles N Serhan Selected Research

CD59 Antigens

1/2021	Protectins PCTR1 and PD1 Reduce Viral Load and Lung Inflammation During Respiratory Syncytial Virus Infection in Mice.
1/2021	Cysteinyl-specialized proresolving mediators link resolution of infectious inflammation and tissue regeneration via TRAF3 activation.
12/2019	Biosynthetic metabolomes of cysteinyl-containing immunoresolvents.
1/2018	The Protectin Family of Specialized Pro-resolving Mediators: Potent Immunoresolvents Enabling Innovative Approaches to Target Obesity and Diabetes.
11/2017	Protectin D1n-3 DPA and resolvin D5n-3 DPA are effectors of intestinal protection.
4/2016	The Protectin PCTR1 Is Produced by Human M2 Macrophages and Enhances Resolution of Infectious Inflammation.
6/2014	Pro-resolving lipid mediators are leads for resolution physiology.
1/2009	Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles N Serhan Research Topics

Disease

206	Inflammation (Inflammations) 04/2022 - 01/2002
27	Infections 01/2022 - 06/2005
27	Peritonitis 01/2021 - 10/2002
16	Neoplasms (Cancer) 01/2022 - 04/2003
14	Pain (Aches) 12/2018 - 11/2003
10	Pneumonia (Pneumonitis) 01/2021 - 09/2002
7	Sepsis (Septicemia) 11/2019 - 10/2009
6	Obesity 01/2021 - 09/2012
6	Atherosclerosis 11/2017 - 10/2008
5	Hypoxia (Hypoxemia) 01/2020 - 06/2002
4	COVID-19 01/2022 - 01/2020
4	Carcinogenesis 01/2021 - 08/2006
4	Neuralgia (Stump Neuralgia) 01/2021 - 04/2012
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 02/2004
4	Colitis 11/2017 - 05/2005
4	Wounds and Injuries (Trauma) 12/2015 - 06/2013
4	Respiratory Hypersensitivity 01/2007 - 09/2002
3	Thrombosis (Thrombus) 01/2022 - 01/2016
3	Cytokine Release Syndrome 01/2021 - 01/2020
3	Lung Injury 01/2021 - 01/2013
3	Stroke (Strokes) 11/2020 - 10/2003
3	Myocardial Infarction 01/2020 - 07/2015
3	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 12/2018 - 11/2014
3	Hyperalgesia 01/2018 - 03/2011
3	Acute Pain 01/2018 - 03/2011
3	Postoperative Pain 01/2018 - 03/2011
3	Periodontitis 11/2017 - 12/2003
3	Ischemia 11/2017 - 10/2003
3	Body Weight (Weight, Body) 10/2017 - 05/2005
3	Edema (Dropsy) 01/2016 - 05/2010
3	Chronic Obstructive Pulmonary Disease (COPD) 12/2015 - 01/2013
3	Reperfusion Injury 05/2015 - 11/2009
3	Acute Lung Injury 11/2014 - 08/2009
3	Asthma (Bronchial Asthma) 01/2007 - 09/2002

Drug/Important Bio-Agent (IBA)

114	LipidsIBA 01/2022 - 01/2002
45	LipoxinsIBA 01/2022 - 01/2002
29	resolvin D1IBA 01/2020 - 03/2007
27	5S,12R,18R- trihydroxy- 6Z,8E,10E,14Z,16E- eicosapentaenoic acidIBA 02/2022 - 03/2005
27	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 10/2019 - 01/2002
22	Docosahexaenoic AcidsIBA 04/2022 - 10/2003
21	CytokinesIBA 01/2022 - 10/2002
20	Eicosapentaenoic AcidIBA 02/2022 - 03/2005
20	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2021 - 06/2006
20	EicosanoidsIBA 01/2021 - 09/2002
18	lipoxin A4IBA 01/2021 - 01/2002
16	protectin D1IBA 01/2021 - 10/2005
15	AutacoidsIBA 01/2022 - 04/2003
15	ProstaglandinsIBA 01/2021 - 09/2002
14	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 02/2022 - 10/2005
14	LeukotrienesIBA 01/2021 - 09/2002
13	ZymosanIBA 01/2021 - 09/2004
13	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 04/2003
10	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2003
9	Arachidonic Acid (Vitamin F)IBA 01/2021 - 02/2004
9	AcidsIBA 01/2020 - 12/2003
8	CD59 AntigensIBA 01/2021 - 01/2009
8	7,14- dihydroxydocosa- 4,8,10,12,16,19- hexaenoic acidIBA 01/2021 - 04/2012
8	EnzymesIBA 12/2019 - 12/2003
7	Leukotriene B4IBA 01/2020 - 04/2003
6	MucinsIBA 01/2021 - 04/2011
6	Carbon MonoxideIBA 12/2018 - 06/2013
6	resolvin D2IBA 01/2018 - 10/2009
5	Biological ProductsIBA 12/2021 - 01/2017
5	Interleukin-13IBA 01/2021 - 09/2002
5	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2021 - 06/2009
5	ChemokinesIBA 01/2019 - 11/2006
5	Arachidonate 15-Lipoxygenase (Arachidonate 15 Lipoxygenase)IBA 11/2017 - 12/2003
5	MicroRNAs (MicroRNA)IBA 11/2013 - 02/2011
4	LigandsIBA 02/2022 - 11/2006
4	resolvin D3IBA 12/2021 - 01/2016
4	Essential Fatty AcidsIBA 01/2021 - 08/2006
4	Biomarkers (Surrogate Marker)IBA 11/2020 - 06/2006
4	LipoxygenasesIBA 01/2020 - 02/2004
4	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2019 - 11/2002
4	Analgesics (Analgesic Drugs)IBA 01/2018 - 05/2010
4	Prostaglandins EIBA 11/2008 - 09/2004
3	resolvin D4IBA 12/2021 - 01/2016
3	Lipoxygenase (Lipoxygenase-1)IBA 01/2021 - 02/2004
3	Methacholine Chloride (Methacholine)FDA Link 01/2020 - 01/2007
3	Formyl Peptide Receptors (Formyl Peptide Receptor)IBA 01/2020 - 06/2009
3	Fish OilsIBA 01/2018 - 03/2005
3	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2018 - 11/2011
3	Dinoprostone (PGE2)FDA Link 01/2017 - 04/2003
3	CarrageenanIBA 07/2016 - 08/2009
3	SmokeIBA 12/2015 - 01/2013
3	Interleukin-5 (Interleukin 5)IBA 02/2015 - 09/2002
3	Interleukin-10 (Interleukin 10)IBA 12/2014 - 05/2012
3	EstersIBA 10/2014 - 06/2008
3	17- hydroxy- 4,7,10,13,15,19- docosahexaenoic acidIBA 06/2013 - 01/2009
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2010 - 05/2005
3	AllergensIBA 12/2007 - 01/2002
3	Interleukin-12 (IL 12)IBA 06/2005 - 03/2005
2	resolvin E2IBA 02/2022 - 05/2012
2	Epoxide HydrolasesIBA 01/2021 - 01/2020
2	EmulsionsIBA 01/2021 - 11/2020

Therapy/Procedure

25	Therapeutics 01/2022 - 12/2003
5	Drug Therapy (Chemotherapy) 11/2021 - 04/2012
4	Ligation 01/2017 - 10/2009
3	Intraperitoneal Injections 01/2021 - 08/2009
3	Punctures 01/2017 - 10/2009